ArticleDermatology and therapy2026
AI-Assisted Quantitative Reflectance Confocal Microscopy Reveals Modulation of Senescence-Associated Epidermal Morphometric Features by a Topical TGF-β Mimetic, XEP™-716 Miniprotein™.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEpidermal aging is characterized by progressive structural alterations, including reduced keratinocyte density, altered cellular morphology, and widened intercellular spacing (ICS). Reflectance confocal microscopy (RCM) combined with artificial intelligence (AI)-assisted image analysis enables non-invasive quantification of these changes in vivo. This secondary analysis of RCM images reported in a previously published randomized split-face clinical trial aimed to identify quantitative morphometric features associated with chronological aging and to evaluate their modulation following topical application of the transforming growth factor-beta (TGF-β) mimetic XEP™-716 Miniprotein™ (Activen SA, Lausanne. Switzerland).
methodsPreviously acquired baseline RCM images from 49 women (age 40-60 years) were analyzed for associations with chronological age. Treatment effects were assessed in 25 women from the 2.5% arm of a 56-day randomized, double-blind, split-face study comparing XEP™-716 Miniprotein™ 2.5% with vehicle. AI-assisted image analysis quantified keratinocyte density, cellular circularity, and ICS in the stratum granulosum (SG) and the stratum spinosum (SS). Cells with circularity ≤ 0.439 were classified as low-circularity cells and those ≥ 0.440 circularity as morphologically normal. Treatment effects were assessed using linear mixed-effects models.
resultsStratum granulosum total and normal keratinocyte densities were nominally significantly associated with age (p = 0.015 and p = 0.023, respectively). Compared with vehicle, XEP™-716 Miniprotein™ used at 2.5% was associated with nominally significant increases in normal keratinocyte density (p = 0.028) and the circularity of low-circularity cells (p = 0.018), and with decreases in ICS thickness (p = 0.030) and low-circularity cell density (p = 0.044) in the SG. In the SS, there was a non-significant trend towards reduced low-circularity cell density (p = 0.075).
conclusionArtificial intelligence-assisted quantitative RCM can identify age-associated epidermal morphometric features, predominantly in the SG, and detect their modulation following topical treatment. XEP™-716 Miniprotein™ at 2.5% showed consistent treatment-associated changes across several morphometric parameters with nominal statistical significance. These exploratory findings warrant prospective validation against molecular senescence markers and functional barrier measurements.
Indexed as
Identifiers
42821227What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.